The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-EGFR antibody linked to CD28 and CD3-zeta signaling domains. The CAR carrying an intracellular domain of a GITR tends to exhibit a higher cytokine production amount relative to the expression amount of the CAR. And the vector product was designed for the treatment of breast cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-MZ012||Anti-EGFR (Nimotuzumab) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
|CAR-MZ073||Anti-EGFRvIII (MR-1) h(CD28-OX40-CD3ζ) CAR, pCDCAR1|
|CAR-LC099||Anti-EGFR (806) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-MZ168||Anti-EGFRvIII/EGFR (225) h(CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC195||Lenti-EGFR CAR (scFv-41BB-CD3ζ) Viral Particle|
|VP-CAR-LC202||Lenti-EGFRvIII CAR (scFv-CD4-FcεRIγ, RAbDMvIII) Viral Particle|
|VP-CAR-LC201||Lenti-EGFRvIII CAR (scFv-CD28-CD3ζ, RAbDMvIII) Viral Particle|
|CAR-MZ079||Anti-EGFRvIII (Y10) h(41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC780||Lenti-EGFRvIII CAR (scFv-CD28-OX40-CD3ζ, 3C10) Viral Particle|
|CAR-MZ007||Anti-EGFR (Cetuximab) h(41BB-CD3ζ) CAR, pCDCAR1|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved